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Abstract:  Although  surgery  or  the  combination  of  chemotherapy  and  radiation  are 
reported to improve the quality of life and reduce symptoms in patients with oral cancer, 
the  prognosis  of  oral  cancer  remains  generally  poor.  DNA  alkylating  agents,  such  as  
N-mustard,  play  an  important  role  in  cancer  drug  development.  BO-1051  is  a  new  
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9-anilinoacridine N-mustard-derivative anti-cancer drug that can effectively target a variety 
of cancer cell lines and inhibit tumorigenesis in vivo. However, the underlying mechanism 
of  BO-1051-mediated  tumor  suppression  remains  undetermined.  In  the  present  study,  
BO-1051 suppressed cell viability with a low IC50 in oral cancer cells, but not in normal 
gingival fibroblasts. Cell cycle analysis revealed that the tumor suppression by BO-1051 
was accompanied by cell cycle arrest and downregulation of stemness genes. The enhanced 
conversion of LC3-I to LC3-II and the formation of acidic vesicular organelles indicated 
that BO-1501 induced autophagy. The expression of checkpoint kinases was upregulated as 
demonstrated  with  Western  blot  analysis,  showing  that  BO-1051  could  induce  DNA 
damage and participate in DNA repair mechanisms. Furthermore, BO-1051 treatment alone 
exhibited  a  moderate  tumor  suppressive  effect  against  xenograft  tumor  growth  in 
immunocompromised mice. Importantly, the combination of BO-1051 and radiation led to 
a potent inhibition on xenograft tumorigenesis. Collectively, our findings demonstrated that 
BO-1051 exhibited a cytotoxic effect via cell cycle arrest and the induction of autophagy. 
Thus, the combination of BO-1051 and radiotherapy may be a feasible therapeutic strategy 
against oral cancer in the future. 
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1. Introduction 
Oral cancer is the sixth most common cancer worldwide, and each year more than half a million 
cases are diagnosed [1]. Oral cancer is one of the most common types of head and neck cancer and is 
defined as malignant tumors occurring within the oral tissue including the lips, tongue, buccal mucosa, 
mouth  floor,  gums,  oropharynx,  hypopharynx,  and  hard  palate.  More  than  ninety  percent  of  oral 
cancers are generated at the mucosal surface; these cancers are often referred to as oral squamous cell 
carcinoma. Sixty percent of these patients present with terminal stage oral cancer [2]. According to the 
statistics published by the Taiwan Department of Health in 2008, there was a significant increase in the 
incidence and mortality of oral cancer in Taiwan over the past decade. In Taiwan, chewing the betel 
nut,  alcohol  consumption,  and  smoking  are  the  major  risk  factors  for  oral  cancer.  According  to 
statistics published in 2008 by the Department of Health, malignant cancer ranks as the leading cause 
of  death  in  Taiwan,  and  oral  cancer  has  the  sixth  highest  mortality  rate.  Although  surgery  or 
combination chemotherapy-radiation therapy can improve the quality of life and reduce symptoms in 
patients with oral cancer, 30 to 50% of patients survive less than three years. 
Currently, the main clinical oral cancer treatments include surgery, radiation therapy, chemotherapy, 
and targeted drug treatment; however, oral cancer patients have high recurrence rates after surgery. 
Importantly,  the  relationships  among  the  molecular  mechanisms  that  induce  cancer  formation  are 
complex.  Thus,  many  pre-clinical  trial  drugs  cannot  fully  destroy  cancer  cells  due  to  molecular 
specificity and the relationship between drug dose and radiation resistance. Therefore, these drugs have 
not been approved for standard clinical use. Int. J. Mol. Sci. 2012, 13  3279 
 
 
DNA alkylating agents play an important role in cancer drug development, with N-mustard being a 
representative agent. However, derivatives of N-mustard, such as melphalan and chlorambucil, have 
poor effects on cancer because they contain a nitrogen group (which is highly nucleophilic) and they 
lack a high degree of affinity to the DNA molecules [3]. Furthermore, these derivatives react easily 
with intracellular proteins or with small sulfur-containing molecules to generate glutathione [4], which 
is mutagenic to genes and toxic to the bone marrow; thus, these derivatives can increase the incidence 
of cancer [5]. Because the structure of N-mustards is not ideal for a candidate drug, scientists used  
N-mustard  derivatives  and  DNA  binding  molecules  such  as  acridines,  anthraquinones,  quinolines, 
phenanthridines, and 9-anilinoacridines to increase the chemical specificity of the drugs [6–8]. Su and 
Klionsky et al. designed and synthesized a series of N-mustard derivatives of 9-anilinoacridine based 
on the evidence mentioned previously. In that study, BO-1051 showed a remarkable ability to target a 
variety of cancer cell lines, including two drug-resistant cell lines, with lower half-maximal inhibitory 
concentration (IC50) than that of normal tissue [9]. In in vivo experiments, BO-1051 had a potent 
antitumor efficacy in nude mice bearing human breast MX-1 xenografts. BO-1051 also effectively 
suppressed human glioma U87MG xenografts in nude mice [9]. However, the underlying mechanism 
of cell death induced by BO-1051 was not determined. 
Clinical anti-cancer drugs target specific molecular characteristics of cancer cells. As the growth 
rate of cancer cells is higher than that of normal tissue, high levels of DNA damage lead to cell cycle 
arrest  and  the  initiation  of  cell  death.  Previous  studies  have  indicated  that  BO-1051,  as  a  DNA 
alkylating agent, can break double-stranded DNA and damage cancer cells, ultimately leading to their 
death [9]. In this study, the cytotoxic effects and mechanism of death induction of the anti-cancer drug 
BO-1051 were investigated in oral cancer cells. In addition, we assessed whether BO-1051 possessed 
tumor suppressive effects in vivo and whether the combination of BO-1051 with cobalt-60 radiation 
had an additive tumor suppressive effect on xenograft tumorigenesis in immunocompromised mice. 
2. Results and Discussion 
2.1. Cytotoxicity of BO-1051 in Oral Cancer Cell Lines 
The structure of BO-1051 is shown in Figure 1. To determine the toxic effects of BO-1051 on oral 
cancer cells, BO-1051 was sequentially diluted with DMSO and then added to the cells and cultured 
for 48 h. A MTT assay was used to analyze the viability of the OECM1 and SAS oral cancer cell lines, 
as  well  as  normal  gingival  fibroblasts,  in  response  to  BO-1051  treatment.  As  shown  in  Figure  2,  
BO-1051 decreased cell viability slightly in normal gingival fibroblasts with an IC50 of 10.82 µM. In 
OECM1  and  SAS,  BO-1051  decreased  cell  viability  robustly  with  IC50  values  of  2.76  µM  and  
1.97  µM,  respectively.  Notably,  the  growth  inhibition  concentration  of  BO-1051  for  the  two  oral 
cancer  cell lines was significantly  lower than that for the normal  gingival fibroblasts,  as reported 
previously  [9].  Based  on  these  results,  we  studied  the  dose  effect  of  BO-1051  (including  0  µM,  
0.1  µM,  0.5  µM,  1.0  µM,  1.5  µM,  2.5  µM,  5  µM,  and  10  µM)  in  subsequent  experiments  and 
investigated the underlying mechanisms of BO-1051-mediated cytotoxicity in oral cancer cells. Int. J. Mol. Sci. 2012, 13  3280 
 
 
Figure 1. The chemical structure of BO-1051. The structural formula of 9-anilinoacridine 
N-mustard-derivative anti-cancer drug BO-1051. 
 
Figure 2. The dose response curve of BO-1051-induced cytotoxicity and determination of 
the IC50 value in normal gingival fibroblasts, SAS cells, and OECM1 cells. BO-1051 was 
sequentially diluted by the addition of DMSO and then added to the cells and cultured for 
48 h. A MTT assay was used to analyze the viability and to determine the IC50 value in the 
oral cancer cell lines SAS and OECM1, as well as normal gingival fibroblasts, in response 
to BO-1051 treatment. The IC50 value of SAS cells, OECM1 cells, and normal gingival 
fibroblasts were 2.39 µM, 1.97 µM, and 10.82 µM, respectively. 
 Int. J. Mol. Sci. 2012, 13  3281 
 
 
2.2. Diverse Effect of BO-1051 on Cell Cycle in Normal Gingival Fibroblasts and Oral Cancer Cells 
To investigate the BO-1051-mediated cytotoxic effect on oral cancer cells further, we evaluated the 
effect of BO-1051 on the growth of oral cancer cells by conducting cell cycle analysis. In normal 
gingival fibroblasts, BO-1051 did not show an observable effect on cell cycle progression (Figure 3A). 
In both SAS and OECM1 cells (Figure 3B,C), correlating with increasing doses of BO-1051, the cell 
number in G0/G1 phase gradually reduced, while the cell number in S and G2/M phases increased, 
indicating a G2/M cell cycle arrest. At doses higher than 2.5 µM, the G2/M cell cycle arrest was 
further enhanced, and S phase cell cycle arrest was induced. There was no increase of cells in the  
sub-G1 phase with the different doses of BO-1051 (Figure 3). These data suggested that BO-1051 has 
an inhibitory role on oral cancer cells partially via the induction of cell cycle arrest. 
Figure 3. The effect of BO-1051 on the cell cycle profile of normal gingival fibroblasts, 
SAS  cells,  and  OECM1  cells.  (A)  Normal  gingival  fibroblasts;  (B)  SAS  cells  or  
(C) OECM1 cells were exposed to increasing doses of BO-1051 (0 to 10 µM) for 24 h 
before collection and FACS analysis of the propidium iodide-stained cells was performed. 
Notice that BO-1051 induced G2/M cell cycle arrest in oral cancer cells (SAS cells and 
OCEM1 cells) but showed no effect on normal gingival fibroblasts. 
            
2.3. BO-1051 Induced Autophagy in Oral Cancer Cells 
To determine if autophagy was involved in the BO-1051-mediated cytotoxicity, we measured the 
changes  in  the  expression  pattern  of  a  known  reliable  marker  of  autophagosomes  termed  LC3,  a 
mammalian  homolog  of  yeast  Atg8.  Tracking  the  conversion  of  LC3-I  to  LC3-II  is  indicative  of Int. J. Mol. Sci. 2012, 13  3282 
 
 
autophagic  activity.  After  48  h  of  BO-1051  treatment  in  both  SAS  and  OECM1  cells,  the  LC3-I 
expression remained unaltered at all given doses of BO-1051, whereas BO-1051 led to a dose-dependent 
increase in LC3-II, especially at doses higher than the IC50 (Figure 4). These results suggested that 
BO-1501  induced  autophagy  in  both  oral  cancer  cell  lines.  The  development  of  acidic  vesicular 
organelles (AVOs) has been reported to be an additional characteristic of autophagy. Therefore, we 
evaluated the formation of AVOs using acridine orange staining in SAS cells. There was an increase in 
red  fluorescence  in  SAS  cells  after  BO-1051  treatment  (Figure  5A,  left  panel).  Subsequently,  we 
quantified the staining using flow cytometry. BO-1051 treatment increased red fluorescence (Y-axis) 
in  SAS  cells,  indicating  the  formation  of  AVOs  was  induced  by  BO-1051  (Figure  5B).  Parallel 
investigations  with  electron  microscopy  further  confirmed  the  BO-1051-induced  formation  of  
AVOs (Figure 5C). 
Figure 4. The effect of BO-1051 on LC3 I-II protein expression in (A) SAS and (B) OECM1 
cells. The cultures were exposed to BO-1051 for 24 h, and the proteins extracted from 
harvested cells were resolved using SDS-PAGE, transferred to nitrocellulose and probed 
with LC3-I-II-specific antibodies. In response to increasing doses of BO1051 in these two 
oral cancer cell lines, LC3 I expression remained unchanged and LC3 II expression was 
increased in a dose-dependent manner. 
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Figure  5.  BO-1051  induces  formation  of  acidic  vesicular  organelles  (AVOs).  
(A) Induction of AVOs by BO-1051 in SAS cells. The cells were treated with various 
concentrations of BO-1051 and stained with acridine orange. Red fluorescence indicates 
the induction of AVOs; (B) Quantification of acridine orange staining was performed with 
flow cytometry; (C) Electron microscopy confirmed the induction of AVOs. 
           
2.4. BO-1051 Induced Checkpoint Kinase Phosphorylation 
Cell  cycle  checkpoints  are  regulatory  pathways  that  control  the  order  and  timing  of  cell  cycle 
transitions  and  ensure  that  critical  events  such  as  DNA  replication  are  completed  with  high  
fidelity  [10].  When  DNA  damage  occurs,  the  cell  cycle  arrest  and  DNA  repair  checkpoints  are 
activated.  The  proteins  ataxia  telangiectasia-mutated  (ATM)  and  ataxia-telangiectasia  and  
Rad3-related (ATR) activate downstream checkpoint kinase 2 (chk2) and checkpoint kinase 1 (chk1), 
respectively, that undertake the repair of DNA double-strand breaks. As shown in Figure 6, BO-1051 
induces the phosphorylation of both chk1 serine-345 and chk2 threonine-68 in dose-dependent manners, 
in both SAS and OECM1 oral cancer cells. These findings indicated that BO-1051-induced autophagy 
involves activation of the ATM/Chk2 and ATR/Chk1 pathways. A previous study has demonstrated 
that overexpression of stemness markers (e.g., Oct4 and Nanog) correlates with cisplatin resistance and 
cancer stem-like properties in oral squamous cell carcinoma [11]. Quantitative RT-PCR showed that 
BO-1051 treatment decreased the expression of stemness markers including Oct4, Sox2, Nanog and  
c-Myc  and  the  oncogene  Bmi-1,  suggesting  that  BO-1051  suppressed  the  cancer  stem-like  and 
chemoresistant properties in oral cancers (Figure 7). Int. J. Mol. Sci. 2012, 13  3284 
 
 
Figure  6.  The  effect  of  BO-1051  on  chk1  serine-345  and  chk2  threonine-68  protein 
phosphorylation. Cultures were exposed to BO-1051 for 24 h and the proteins extracted 
from  harvested  cells  were  resolved  using  SDS-PAGE,  transferred  to  nitrocellulose  and 
probed  with  Chk1-  and  Chk2-specific  antibodies.  In  response  to  increasing  doses  of 
BO1051  in  SAS  cells  and  OCEM1  cells,  Chk1  serine-345  and  Chk2  threonine-68 
phosphorylation was increased in a dose-dependent manner. 
 
 
Figure 7. The effect of BO-1051 on the gene expression of stemness markers. Quantitative 
RT-PCR analysis of Oct4, Sox, Nanog, c-Myc and the oncogene Bmi-1 in the oral cancer 
cells with or without BO-1051 treatment was performed. 
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2.5. Tumor Suppressive Effects of BO-1051 on the Xenograft Tumors in Mice 
To evaluate the tumor suppressive effects of BO-1051 in vivo, we performed a xenograft tumor 
assay in nude mice. Xenotransplantation of the oral cancer cell line SAS led to significant tumor 
formation in recipients, and the recipients with tumor volumes greater than 150 mm
3 were randomized 
into the following four groups: control group; BO-1051 group (50 mg/kg b. w., given at intervals of 2 
to  3  days);  irradiation  group  (receiving  4  Gy  radiation);  and  the  combination  of  BO-1051  and 
irradiation group (50 mg/kg BO-1051 treatment as described above with 4 Gy radiation). The tumor 
volume  of  the  control  group  increased  from  the  average  volume  200–250  mm
3  to  1000  mm
3  in 
approximately 11 days. The tumor volume of the BO-1051 group increased to a comparable volume at 
22 days, the irradiation group in 14 days, and the BO-1051 plus radiation in 26 days. The longer time 
course required for the tumor growth in the BO-1051 plus radiation group demonstrated that BO-1051 
moderately  suppressed  tumorigenesis  in  vivo  and  the  combination  of  BO-1051  and  radiation 
potentially suppressed the progression of xenograft tumor growth in mice (Figure 8). 
Figure 8. Effect of BO-1051 and/or radiation on xenograft tumors in mice. Nude mice 
were subcutaneously transplanted with 5 × 10
5 SAS cells and randomized into 4 groups: 
control, radiation (4 Gy), BO-1051 (50 mg/kg) or BO-1051 plus radiation (50 mg/kg and  
4  Gy,  respectively).  Thirteen  days  after  implantation,  the  mice  were  intraperitoneally 
treated with BO-1051 once every two days for three courses of treatment (as indicated by 
arrow on days 13, 16 and 19 after implantation). Radiation (4 Gy) was delivered 24 h after 
the  second  injection  of  BO-1051.  Note  that  BO-1051  alone  extended  the  time  course 
required for the tumor growth, indicating that this drug suppressed tumorigenesis in vivo. 
The  combination  of  BO-1051  plus  radiation  further  suppressed  the  progression  of  
tumor growth. 
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2.6. Discussion 
BO-1051 is a new DNA-affinic molecule and an N-mustard alkylating agent that is used as an  
anti-cancer  drug.  BO-1051  was  created  by  combining  two  clinical  cancer  drugs,  N-mustard  and  
9-anilinoacridine. Bifunctional alkylating agents induce collapsed replication forks that can lead to cell 
cycle  arrest,  DNA  repair,  or  apoptosis  [12].  Bifunctional  N-mustard  alkylating  agents,  such  as  
BO-1051, are able to induce marked dose-dependent levels of DNA interstrand cross-linking, resulting 
in a broad spectrum of anti-cancer activities in vitro [13,14]. BO-1051 has been shown to possess 
therapeutic efficacy in nude mice bearing human breast MX-1 tumors and human glioma in vivo [9]. In 
recent years, the combination of radiation therapy with anti-cancer drugs has also advanced for the 
clinical  treatment  of  cancer.  Cisplatin,  which  has  a  mechanism  of  action  similar  to  that  of  the  
N-mustards,  is  used  in  the  clinical  treatment  of  oral  cancer  patients  and  is  often  combined  with 
radiation treatment. In the present study, we investigated the synergistic cytotoxic effects of BO-1051 
and radiation on oral cancer cells and tumor xenografts. 
The mechanism of the BO-1051-induced cytotoxic effect has been reported in glioma cells [15] and 
hepatocellular carcinoma cells [16]. BO-1051 has been shown to inhibit the growth of glioma cells, 
which are notorious for the high resistance to radiotherapy. Our recent study further demonstrated that 
BO-1051 significantly enhanced the radiosensitivity of tumor cells. The enhanced radiosensitivity was 
found to be associated with a G2/M phase arrest as well as sustained DNA damage. In vivo studies 
further demonstrated that BO-1051 enhanced the radiotherapeutic effects on glioma-bearing xenograft 
tumors [15]. In hepatocellular carcinoma cell lines, BO-1051 simultaneously induced apoptosis and 
autophagy. DNA double strand breaks induced by BO-1051 activated the ATM signaling pathway and 
subsequently resulted in caspase-dependent apoptosis [16]. In the present study using oral cancer cell 
lines, G2/M phase arrest, induction of autophagy, as well as radiosensitization was observed, which 
was  similar  to  our  previous  findings  [15].  We  further  demonstrated  that  BO-1051  decreased  the 
expression of stemness markers, suggesting that such potential chemotherapeutic drug also suppressed 
cancer stem-like and chemoresistant properties. However, there was no obvious evidence showing that 
BO-1051 led to apoptosis in such cells. These findings indicated that the mechanisms mediating the 
BO-1051-induced cytotoxicity could be cell-specific. 
In this study, the induction of autophagy was demonstrated by the conversion of LC3-I to LC3-II, 
with the flow cytometry data and electron microscopic evidence showing the development of AVOs. 
Nevertheless, the role of autophagy has been contested by numerous studies because autophagy has 
been reported to be either prodeath or prosurvival [17]. In hepatocellular carcinoma cell lines, autophagy 
can be induced by various compounds and can be involved in cell death or cytoprotection [18–20]. 
Inhibition of autophagy at different stages has been reported to have opposite effects on cell survival [21]. 
Our previous findings in hepatocellular carcinoma also showed that inhibition of autophagy leads to 
enhanced apoptosis in both early and late stages, indicating that autophagy is not strictly a prodeath 
mechanism  [16].  However,  in  glioma  [22,23]  and  lung  cancers  [24],  there  were  several  lines  of 
evidence supporting autophagy as one of the causes of radiosensitization instead of apoptosis, which 
was compatible with our findings of BO-1051-induced radiosensitization in oral cancer cells in the 
present study. Therefore, the correlation between cytotoxicity, autophagy, and radiosensitivity induced 
by BO-1051 needs to be further investigated. In future investigations, it will be necessary to elucidate Int. J. Mol. Sci. 2012, 13  3287 
 
 
the differential damage, such as the interstrand DNA crosslinking in normal and cancer cells, the bone 
marrow and hematological toxicity in vivo, and the resistance determinants such as the glutathione and 
glutathione S-transferase levels. Studies like these may assist to determine the feasibility and potential 
of this DNA-reactive compound for clinical use. 
3. Materials and Methods 
3.1. MTT Assay 
The cells were seeded in 96-well (6000 cells per well) or 24-well (30,000 cells per well) plates in 
complete culture medium. After overnight culture, the medium was replaced with either solvent or 
chemicals at indicated concentrations in complete medium. The cells were  cultured until the time 
indicated, and an MTT assay was performed. In brief, cells were stained with 0.1 mg/mL MTT (Sigma) 
for 2–4 h and then dissolved in DMSO  (Sigma). MTT values were measured  at 570 nm using a 
microplate reader. 
3.2. Cell-Cycle Analysis 
After treatment, the cells were prepared for fluorescence-activated cell sorting (FACS) to assess the 
relative distribution in the respective phases of the cell cycle. Cells were harvested 24 h after treatment 
with BO-1051, pelleted using centrifugation, resuspended in PBS, fixed in 70% ethanol and stored at 
−20 °C. Immediately before flow cytometric analysis, the cells were washed in cold PBS (4 °C), 
incubated in Ribonuclease A (Sigma) for 20 min at room temperature, labeled by adding an equal 
volume of propidium iodide solution (100 µg/mL) and incubated in the dark for 20 min at 4 °C. These 
samples were measured (20,000 events collected from each) in a FACSCalibur cytometer (BD FACS 
Caliber; Mountain View, CA, USA). The data shown are for one experiment, but the results were 
reproduced and confirmed in at least three identical experiments. 
3.3. Immunoblot Analysis 
Harvested cells were pelleted using centrifugation, washed with PBS, and lysed with RIPA buffer. 
Protein content was measured with a protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). 
Fifty micrograms of total protein were separated by SDS/PAGE (10% or 12% gels) and transferred to 
nitrocellulose membranes (Pall Corporation, Ann Arbor, MI, USA) for immunological detection of 
proteins. The blots were probed using antibodies against cleaved PARP, cleaved caspase-3, and beta-
actin (Millipore Corporation, Milford, MA, USA). 
3.4. In Vivo Tumorigenesis Model 
Six-week-old female nude mice were used in these studies. Mice were caged in groups of five or 
less, and all animals were fed a diet of animal chow and water ad libitum. All procedures involving 
animals were performed in accordance with the institutional animal welfare guidelines of the Taipei 
Veterans General Hospital. Tumors were generated by injecting 5 × 10
6 SAS cells subcutaneous (s.c.) Int. J. Mol. Sci. 2012, 13  3288 
 
 
into the right hind leg. Irradiation was performed using a T-1000 Theratronic cobalt unit (Theratronic 
International, Inc.; Ottawa, Canada) irradiator with animals restrained in a custom jig. 
3.5. Statistical Analysis 
Data  were  expressed  as  mean  ±  SD  from  at  least  three  independent  experiments.  Significant 
differences between groups were detected by using the AVONA or unpaired Student’s t tests. The 
results were considered statistically significant at p < 0.05. 
4. Conclusions 
Oral  cancer  is  the  sixth  most  common  cancer  worldwide  and  usually  is  accompanied  with  an 
extremely poor prognosis. Our findings demonstrated that BO-1051 inhibited the growth of oral cancer 
cells with G2/M phase arrest, downregulation of stemness markers and upregulation of checkpoint 
kinases, indicating that BO-1051 can induce DNA damage and participate in DNA repair mechanisms. 
Our in vitro findings also demonstrated that BO-1051-induced autophagy, which is highly associated 
with radiosensitization in other cell lines. Furthermore, in vivo studies demonstrated that BO-1051 
enhanced the radiotherapeutic effects on SAS xenograft tumors in immunocompromised mice. In this 
model, the combination of BO-1051 plus radiation produced the best therapeutic response. These data 
suggest that BO-1051 provides a new strategy to improve therapeutic efficacy by radiation therapy. 
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